Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 10/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12650392 | 1.00 | MAPK1 (0.50) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492939 | 0.87 | MAPK1 (0.62) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12650261 | 0.87 | MAPK1 (0.62) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492929 | 0.86 | MAPK1 (0.60) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL12650369 | 0.83 | PSEN1 (0.50) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1493026 | 0.83 | PSEN1 (0.50) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492979 | 0.82 | PSEN1 (0.54) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1779524 | 0.81 | PSEN1 (0.53) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1492763 | 0.81 | PSEN1 (0.53) | MAPK1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1780009 | 0.81 | PSEN1 (0.53) | MAPK1PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102083794-A | Urea compounds as gamma secretase modulators | AMGEN INC | 2011-06-01 | — | — | CN | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | claimed |
| EP-2300427-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2011-03-30 | — | — | EP | claimed |
| WO-2009137404-A1 | UREA COMPOUNDS AS GAMMA SECRETASE MODULATORS | AMGEN INC. (US) | 2009-11-12 | — | — | WO | claimed |
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118234-A1 | Urea Compounds as Gamma Secretase Modulators | BACE1, BACE2, PSEN1 | MAPK1 3550/4885PSEN1 3/4885PSEN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.